Beyond Joint Inflammation: Does Early RA Control Prevent Chronic Pain and Fatigue? Save

Could the therapeutic window of opportunity in rheumatoid arthritis extend beyond preventing structural damage to preventing chronic pain, fatigue, and neuroimmune complications?

This is the provocative question raised by a study presented at ACR Convergence 2026 (Abstract #0491), using data from the French ESPOIR early rheumatoid arthritis (RA) cohort.

We have long recognized the importance of early diagnosis, prompt DMARD initiation, and treat-to-target strategies. However, even when inflammation is adequately controlled, many patients continue to experience persistent pain, fatigue, and psychological distress. These manifestations frequently contribute to difficult-to-treat RA and represent a major unmet clinical need.

Could delayed inflammatory control contribute to their development?

What Did the ESPOIR Study Show?

Dubourg and colleagues analyzed 813 patients with early RA from the ESPOIR cohort, followed for five years.The investigators examined whether time to achieving low disease activity (LDA) was associated with subsequent development of non-inflammatory chronic pain, fibromyalgia, chronic fatigue, and anxiety-depressive disorders.

These complications were common:

Chronic non-inflammatory pain: 4.9%
Fibromyalgia: 6.9%
Chronic fatigue: 23.5%
Anxiety-depressive disorders: 28.7%

Importantly, each additional month required to achieve LDA was associated with increased odds of fibromyalgia (adjusted OR 1.04; 95% CI 1.02–1.07), chronic fatigue (OR 1.03; 95% CI 1.02–1.05), and anxiety-depressive disorders (OR 1.03; 95% CI 1.01–1.05).

Achieving remission was associated with substantially lower odds of anxiety-depressive disorders (OR 0.39), fibromyalgia (OR 0.19), and chronic fatigue (OR 0.42). Delayed DMARD initiation was also associated with chronic fatigue, with an adjusted OR of 1.02 per additional week.

These findings suggest that the duration of uncontrolled inflammation may influence outcomes extending well beyond conventional measures of disease activity.

My Perspective: Rethinking the Window of Opportunity

For me, the most interesting aspect of this study is not simply the confirmation that earlier disease control is better. It is the possibility that prolonged inflammation may contribute to the transition from inflammatory disease activity to persistent, partially inflammation-independent symptom burden.

In clinical practice, we frequently encounter patients whose swollen joint counts and inflammatory markers have improved, yet pain and fatigue remain substantial. We often interpret these manifestations as comorbid conditions requiring separate management. That distinction remains essential. However, this study raises another possibility: could some of these complications be influenced by the inflammatory trajectory established early in the disease?

Potential mechanisms include central sensitization, neuroimmune interactions, altered pain processing, and persistent changes in inflammatory signaling.

The ESPOIR findings are compatible with this hypothesis, although they do not establish these mechanisms or demonstrate causality.

An additional finding deserves caution. Early corticosteroid exposure was associated with lower odds of subsequent non-inflammatory chronic pain, but this association was not maintained in sensitivity analyses. Therefore, these results should not be interpreted as supporting corticosteroids specifically to prevent chronic pain.

What Should Rheumatologists Take Into Practice?

First, time matters. Delays in achieving inflammatory control may have consequences beyond radiographic progression. Early DMARD initiation and systematic treatment optimization remain essential.

Second, remission matters. Achieving remission, rather than accepting prolonged residual inflammatory activity, may be associated with a lower subsequent burden of fatigue, fibromyalgia-like symptoms, and psychological distress.

Third, assess symptoms beyond inflammation. Pain, fatigue, sleep, mood, and functional limitations should be evaluated from the earliest stages of RA, not only when patients become difficult to treat.

Fourth, avoid therapeutic escalation based solely on persistent symptoms. Once objective inflammation is controlled, persistent pain and fatigue require careful assessment for non-inflammatory mechanisms and comorbidities.

Finally, we must recognize the limitations: this was an observational analysis, and several outcomes relied on operational definitions rather than formal clinical diagnoses. Residual confounding and reverse causation cannot be excluded.

The Take-Home Message

Perhaps the window of opportunity in early RA is not only about preventing irreversible joint damage. It may also be about reducing the future burden of persistent pain, fatigue, and neuroimmune complications.

The ESPOIR study does not prove that rapid inflammatory control prevents these outcomes. But it provides another compelling reason to pursue early, sustained disease control while integrating patient-reported outcomes into routine care.

Our goal should not simply be to achieve better disease activity scores. It should be to change the long-term trajectory of the patient’s disease experience.